An open-label trial to test menstrual cycle effects and tolerance to MB22001 microdosing in healthy people with a menstrual cycle
Latest Information Update: 07 May 2024
At a glance
- Drugs Lysergide (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms MDMENS
- 07 May 2024 New trial record
- 30 Apr 2024 According to MindBio Therapeutics media release, the company announces the regulatory approval of this trial